#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Influenza A virus ( IAV ) , a member of the Orthomyxoviridae family , is a negative-sense , single-stranded , enveloped , segmented RNA virus .
2-1	16-25	Influenza	abstract	new	appos	2-2[3_0]
2-2	26-27	A	abstract[3]	giv[3]	appos	2-5[0_3]
2-3	28-33	virus	abstract[3]	giv[3]	_	_
2-4	34-35	(	_	_	_	_
2-5	36-39	IAV	abstract	giv	coref	2-16[7_0]
2-6	40-41	)	_	_	_	_
2-7	42-43	,	_	_	_	_
2-8	44-45	a	person[5]	new[5]	_	_
2-9	46-52	member	person[5]	new[5]	_	_
2-10	53-55	of	person[5]	new[5]	_	_
2-11	56-59	the	person[5]|abstract[6]	new[5]|new[6]	_	_
2-12	60-76	Orthomyxoviridae	person[5]|abstract[6]	new[5]|new[6]	_	_
2-13	77-83	family	person[5]|abstract[6]	new[5]|new[6]	_	_
2-14	84-85	,	_	_	_	_
2-15	86-88	is	_	_	_	_
2-16	89-90	a	abstract[7]	giv[7]	coref	3-1[0_7]
2-17	91-105	negative-sense	abstract[7]	giv[7]	_	_
2-18	106-107	,	abstract[7]	giv[7]	_	_
2-19	108-123	single-stranded	abstract[7]	giv[7]	_	_
2-20	124-125	,	abstract[7]	giv[7]	_	_
2-21	126-135	enveloped	abstract[7]	giv[7]	_	_
2-22	136-137	,	abstract[7]	giv[7]	_	_
2-23	138-147	segmented	abstract[7]	giv[7]	_	_
2-24	148-151	RNA	abstract[7]	giv[7]	_	_
2-25	152-157	virus	abstract[7]	giv[7]	_	_
2-26	158-159	.	_	_	_	_

#Text=IAV usually infects epithelial cells of the upper and lower respiratory tracts , including the nasal mucosa , trachea , and lungs , with no evident symptoms during the early phase of infection .
3-1	160-163	IAV	abstract	giv	coref	4-3
3-2	164-171	usually	_	_	_	_
3-3	172-179	infects	_	_	_	_
3-4	180-190	epithelial	object[9]	new[9]	coref	4-18[22_9]
3-5	191-196	cells	object[9]	new[9]	_	_
3-6	197-199	of	object[9]	new[9]	_	_
3-7	200-203	the	object[9]|object[10]	new[9]|new[10]	_	_
3-8	204-209	upper	object[9]|object[10]	new[9]|new[10]	_	_
3-9	210-213	and	object[9]|object[10]	new[9]|new[10]	_	_
3-10	214-219	lower	object[9]|object[10]	new[9]|new[10]	_	_
3-11	220-231	respiratory	object[9]|object[10]	new[9]|new[10]	_	_
3-12	232-238	tracts	object[9]|object[10]	new[9]|new[10]	_	_
3-13	239-240	,	object[9]|object[10]	new[9]|new[10]	_	_
3-14	241-250	including	object[9]|object[10]	new[9]|new[10]	_	_
3-15	251-254	the	object[9]|object[10]|object[11]	new[9]|new[10]|new[11]	_	_
3-16	255-260	nasal	object[9]|object[10]|object[11]	new[9]|new[10]|new[11]	_	_
3-17	261-267	mucosa	object[9]|object[10]|object[11]	new[9]|new[10]|new[11]	_	_
3-18	268-269	,	object[9]|object[10]	new[9]|new[10]	_	_
3-19	270-277	trachea	object[9]|object[10]|object	new[9]|new[10]|new	_	_
3-20	278-279	,	object[9]|object[10]	new[9]|new[10]	_	_
3-21	280-283	and	object[9]|object[10]	new[9]|new[10]	_	_
3-22	284-289	lungs	object[9]|object[10]|object[13]	new[9]|new[10]|new[13]	_	_
3-23	290-291	,	object[9]|object[10]|object[13]	new[9]|new[10]|new[13]	_	_
3-24	292-296	with	object[9]|object[10]|object[13]	new[9]|new[10]|new[13]	_	_
3-25	297-299	no	object[9]|object[10]|object[13]|abstract[14]	new[9]|new[10]|new[13]|new[14]	_	_
3-26	300-307	evident	object[9]|object[10]|object[13]|abstract[14]	new[9]|new[10]|new[13]|new[14]	_	_
3-27	308-316	symptoms	object[9]|object[10]|object[13]|abstract[14]	new[9]|new[10]|new[13]|new[14]	_	_
3-28	317-323	during	object[9]|object[10]|object[13]|abstract[14]	new[9]|new[10]|new[13]|new[14]	_	_
3-29	324-327	the	object[9]|object[10]|object[13]|abstract[14]|abstract[15]	new[9]|new[10]|new[13]|new[14]|new[15]	_	_
3-30	328-333	early	object[9]|object[10]|object[13]|abstract[14]|abstract[15]	new[9]|new[10]|new[13]|new[14]|new[15]	_	_
3-31	334-339	phase	object[9]|object[10]|object[13]|abstract[14]|abstract[15]	new[9]|new[10]|new[13]|new[14]|new[15]	_	_
3-32	340-342	of	object[9]|object[10]|object[13]|abstract[14]|abstract[15]	new[9]|new[10]|new[13]|new[14]|new[15]	_	_
3-33	343-352	infection	object[9]|object[10]|object[13]|abstract[14]|abstract[15]|abstract	new[9]|new[10]|new[13]|new[14]|new[15]|new	coref	5-12[28_0]
3-34	353-354	.	_	_	_	_

#Text=Once an influenza virus invasion occurs , innate immunity is activated , and interferons are secreted by host cells to limit the early viral proliferation .
4-1	355-359	Once	_	_	_	_
4-2	360-362	an	event[19]	new[19]	_	_
4-3	363-372	influenza	abstract|event[19]	giv|new[19]	coref	4-4
4-4	373-378	virus	abstract|event[19]	giv|new[19]	coref	6-9
4-5	379-387	invasion	event[19]	new[19]	_	_
4-6	388-394	occurs	_	_	_	_
4-7	395-396	,	_	_	_	_
4-8	397-403	innate	abstract[20]	new[20]	coref	5-3[25_20]
4-9	404-412	immunity	abstract[20]	new[20]	_	_
4-10	413-415	is	_	_	_	_
4-11	416-425	activated	_	_	_	_
4-12	426-427	,	_	_	_	_
4-13	428-431	and	_	_	_	_
4-14	432-443	interferons	substance	new	_	_
4-15	444-447	are	_	_	_	_
4-16	448-456	secreted	_	_	_	_
4-17	457-459	by	_	_	_	_
4-18	460-464	host	object[22]	giv[22]	coref	7-6[42_22]
4-19	465-470	cells	object[22]	giv[22]	_	_
4-20	471-473	to	_	_	_	_
4-21	474-479	limit	_	_	_	_
4-22	480-483	the	abstract[24]	new[24]	coref	10-12[78_24]
4-23	484-489	early	abstract[24]	new[24]	_	_
4-24	490-495	viral	organization|abstract[24]	new|new[24]	coref	5-12
4-25	496-509	proliferation	abstract[24]	new[24]	_	_
4-26	510-511	.	_	_	_	_

#Text=Then , adaptive immunity is activated by other cytokines produced during viral infection .
5-1	512-516	Then	_	_	_	_
5-2	517-518	,	_	_	_	_
5-3	519-527	adaptive	abstract[25]	giv[25]	coref	17-14[144_25]
5-4	528-536	immunity	abstract[25]	giv[25]	_	_
5-5	537-539	is	_	_	_	_
5-6	540-549	activated	_	_	_	_
5-7	550-552	by	_	_	_	_
5-8	553-558	other	abstract[26]	new[26]	coref	6-21[36_26]
5-9	559-568	cytokines	abstract[26]	new[26]	_	_
5-10	569-577	produced	_	_	_	_
5-11	578-584	during	_	_	_	_
5-12	585-590	viral	object|abstract[28]	giv|giv[28]	coref|coref|coref|coref	7-41|10-3[76_28]|7-41|10-3[76_28]
5-13	591-600	infection	abstract[28]	giv[28]	_	_
5-14	601-602	.	_	_	_	_

#Text=However , in some cases , highly pathogenic influenza viruses induce cytokine storms , a consequence of excessive production of cytokines and interferon , resulting in infections and even death .
6-1	603-610	However	_	_	_	_
6-2	611-612	,	_	_	_	_
6-3	613-615	in	_	_	_	_
6-4	616-620	some	abstract[29]	new[29]	_	_
6-5	621-626	cases	abstract[29]	new[29]	_	_
6-6	627-628	,	_	_	_	_
6-7	629-635	highly	object[31]	new[31]	coref	8-7[58_31]
6-8	636-646	pathogenic	object[31]	new[31]	_	_
6-9	647-656	influenza	abstract|object[31]	giv|new[31]	coref	7-3
6-10	657-664	viruses	object[31]	new[31]	_	_
6-11	665-671	induce	_	_	_	_
6-12	672-680	cytokine	substance|abstract[33]	new|new[33]	appos|appos	6-15[34_33]|6-15[34_33]
6-13	681-687	storms	abstract[33]	new[33]	_	_
6-14	688-689	,	_	_	_	_
6-15	690-691	a	abstract[34]	giv[34]	_	_
6-16	692-703	consequence	abstract[34]	giv[34]	_	_
6-17	704-706	of	abstract[34]	giv[34]	_	_
6-18	707-716	excessive	abstract[34]|abstract[35]	giv[34]|new[35]	_	_
6-19	717-727	production	abstract[34]|abstract[35]	giv[34]|new[35]	_	_
6-20	728-730	of	abstract[34]|abstract[35]	giv[34]|new[35]	_	_
6-21	731-740	cytokines	abstract[34]|abstract[35]|abstract[36]	giv[34]|new[35]|giv[36]	_	_
6-22	741-744	and	abstract[34]|abstract[35]|abstract[36]	giv[34]|new[35]|giv[36]	_	_
6-23	745-755	interferon	abstract[34]|abstract[35]|abstract[36]|organization	giv[34]|new[35]|giv[36]|new	_	_
6-24	756-757	,	_	_	_	_
6-25	758-767	resulting	_	_	_	_
6-26	768-770	in	_	_	_	_
6-27	771-781	infections	abstract	new	_	_
6-28	782-785	and	_	_	_	_
6-29	786-790	even	event[39]	new[39]	_	_
6-30	791-796	death	event[39]	new[39]	_	_
6-31	797-798	.	_	_	_	_

#Text=To facilitate virus replication in the host cells , IAV has evolved strategies to block the innate and adaptive immune responses of the host cells and seize organelles from host cells to synthesize a large number of metabolites required for viral reproduction , as well as energy for the packaging of the virus .
7-1	799-801	To	_	_	_	_
7-2	802-812	facilitate	_	_	_	_
7-3	813-818	virus	abstract|abstract[41]	giv|new[41]	coref|coref|coref|coref	7-10|8-29[66_41]|7-10|8-29[66_41]
7-4	819-830	replication	abstract[41]	new[41]	_	_
7-5	831-833	in	_	_	_	_
7-6	834-837	the	object[42]	giv[42]	coref	7-23[47_42]
7-7	838-842	host	object[42]	giv[42]	_	_
7-8	843-848	cells	object[42]	giv[42]	_	_
7-9	849-850	,	_	_	_	_
7-10	851-854	IAV	organization	giv	coref	7-52[56_0]
7-11	855-858	has	_	_	_	_
7-12	859-866	evolved	_	_	_	_
7-13	867-877	strategies	abstract	new	coref	17-27[149_0]
7-14	878-880	to	_	_	_	_
7-15	881-886	block	_	_	_	_
7-16	887-890	the	abstract[46]	new[46]	_	_
7-17	891-897	innate	abstract[46]	new[46]	_	_
7-18	898-901	and	abstract[46]	new[46]	_	_
7-19	902-910	adaptive	abstract[46]	new[46]	_	_
7-20	911-917	immune	abstract|abstract[46]	new|new[46]	coref	16-14
7-21	918-927	responses	abstract[46]	new[46]	_	_
7-22	928-930	of	abstract[46]	new[46]	_	_
7-23	931-934	the	abstract[46]|object[47]	new[46]|giv[47]	coref	7-30[49_47]
7-24	935-939	host	abstract[46]|object[47]	new[46]|giv[47]	_	_
7-25	940-945	cells	abstract[46]|object[47]	new[46]|giv[47]	_	_
7-26	946-949	and	_	_	_	_
7-27	950-955	seize	_	_	_	_
7-28	956-966	organelles	object	new	_	_
7-29	967-971	from	_	_	_	_
7-30	972-976	host	object[49]	giv[49]	coref	9-11[72_49]
7-31	977-982	cells	object[49]	giv[49]	_	_
7-32	983-985	to	_	_	_	_
7-33	986-996	synthesize	_	_	_	_
7-34	997-998	a	abstract[50]	new[50]	_	_
7-35	999-1004	large	abstract[50]	new[50]	_	_
7-36	1005-1011	number	abstract[50]	new[50]	_	_
7-37	1012-1014	of	abstract[50]	new[50]	_	_
7-38	1015-1026	metabolites	abstract[50]|substance	new[50]|new	coref	8-10[60_0]
7-39	1027-1035	required	abstract[50]	new[50]	_	_
7-40	1036-1039	for	abstract[50]	new[50]	_	_
7-41	1040-1045	viral	abstract[50]|organization|abstract[53]	new[50]|giv|new[53]	_	_
7-42	1046-1058	reproduction	abstract[50]|abstract[53]	new[50]|new[53]	_	_
7-43	1059-1060	,	abstract[50]	new[50]	_	_
7-44	1061-1063	as	abstract[50]	new[50]	_	_
7-45	1064-1068	well	abstract[50]	new[50]	_	_
7-46	1069-1071	as	abstract[50]	new[50]	_	_
7-47	1072-1078	energy	abstract[50]|abstract[54]	new[50]|new[54]	_	_
7-48	1079-1082	for	abstract[50]|abstract[54]	new[50]|new[54]	_	_
7-49	1083-1086	the	abstract[50]|abstract[54]|abstract[55]	new[50]|new[54]|new[55]	_	_
7-50	1087-1096	packaging	abstract[50]|abstract[54]|abstract[55]	new[50]|new[54]|new[55]	_	_
7-51	1097-1099	of	abstract[50]|abstract[54]|abstract[55]	new[50]|new[54]|new[55]	_	_
7-52	1100-1103	the	abstract[50]|abstract[54]|abstract[55]|abstract[56]	new[50]|new[54]|new[55]|giv[56]	coref	9-19[74_56]
7-53	1104-1109	virus	abstract[50]|abstract[54]|abstract[55]|abstract[56]	new[50]|new[54]|new[55]|giv[56]	_	_
7-54	1110-1111	.	_	_	_	_

#Text=Enveloped , non-enveloped , DNA and RNA viruses share lipid metabolites in their replication cycles to induce the formation of new cytoplasmic membrane structures , which contribute to the replication and packaging of the viral genome .
8-1	1112-1121	Enveloped	_	_	_	_
8-2	1122-1123	,	_	_	_	_
8-3	1124-1137	non-enveloped	_	_	_	_
8-4	1138-1139	,	_	_	_	_
8-5	1140-1143	DNA	substance	new	_	_
8-6	1144-1147	and	_	_	_	_
8-7	1148-1151	RNA	object[58]	giv[58]	coref	12-33[103_58]
8-8	1152-1159	viruses	object[58]	giv[58]	_	_
8-9	1160-1165	share	_	_	_	_
8-10	1166-1171	lipid	person|substance[60]	new|giv[60]	ana|coref|ana|coref	8-13[0_60]|9-1|8-13[0_60]|9-1
8-11	1172-1183	metabolites	substance[60]	giv[60]	_	_
8-12	1184-1186	in	_	_	_	_
8-13	1187-1192	their	substance|abstract[62]	giv|new[62]	coref|coref	11-5[84_0]|11-5[84_0]
8-14	1193-1204	replication	abstract[62]	new[62]	_	_
8-15	1205-1211	cycles	abstract[62]	new[62]	_	_
8-16	1212-1214	to	_	_	_	_
8-17	1215-1221	induce	_	_	_	_
8-18	1222-1225	the	abstract[63]	new[63]	_	_
8-19	1226-1235	formation	abstract[63]	new[63]	_	_
8-20	1236-1238	of	abstract[63]	new[63]	_	_
8-21	1239-1242	new	abstract[63]|abstract[65]	new[63]|new[65]	_	_
8-22	1243-1254	cytoplasmic	abstract[63]|abstract[65]	new[63]|new[65]	_	_
8-23	1255-1263	membrane	abstract[63]|object|abstract[65]	new[63]|new|new[65]	_	_
8-24	1264-1274	structures	abstract[63]|abstract[65]	new[63]|new[65]	_	_
8-25	1275-1276	,	_	_	_	_
8-26	1277-1282	which	_	_	_	_
8-27	1283-1293	contribute	_	_	_	_
8-28	1294-1296	to	_	_	_	_
8-29	1297-1300	the	abstract[66]	giv[66]	coref	9-15[73_66]
8-30	1301-1312	replication	abstract[66]	giv[66]	_	_
8-31	1313-1316	and	_	_	_	_
8-32	1317-1326	packaging	abstract[67]	new[67]	_	_
8-33	1327-1329	of	abstract[67]	new[67]	_	_
8-34	1330-1333	the	abstract[67]|object[68]	new[67]|new[68]	_	_
8-35	1334-1339	viral	abstract[67]|object[68]	new[67]|new[68]	_	_
8-36	1340-1346	genome	abstract[67]|object[68]	new[67]|new[68]	_	_
8-37	1347-1348	.	_	_	_	_

#Text=Lipid metabolism also can block the innate immune response of host cells to ensure the large-scale replication of the virus .
9-1	1349-1354	Lipid	object|abstract[70]	giv|new[70]	coref|coref	10-9[0_70]|10-9[0_70]
9-2	1355-1365	metabolism	abstract[70]	new[70]	_	_
9-3	1366-1370	also	_	_	_	_
9-4	1371-1374	can	_	_	_	_
9-5	1375-1380	block	_	_	_	_
9-6	1381-1384	the	abstract[71]	new[71]	_	_
9-7	1385-1391	innate	abstract[71]	new[71]	_	_
9-8	1392-1398	immune	abstract[71]	new[71]	_	_
9-9	1399-1407	response	abstract[71]	new[71]	_	_
9-10	1408-1410	of	abstract[71]	new[71]	_	_
9-11	1411-1415	host	abstract[71]|object[72]	new[71]|giv[72]	coref	13-20[0_72]
9-12	1416-1421	cells	abstract[71]|object[72]	new[71]|giv[72]	_	_
9-13	1422-1424	to	_	_	_	_
9-14	1425-1431	ensure	_	_	_	_
9-15	1432-1435	the	abstract[73]	giv[73]	_	_
9-16	1436-1447	large-scale	abstract[73]	giv[73]	_	_
9-17	1448-1459	replication	abstract[73]	giv[73]	_	_
9-18	1460-1462	of	abstract[73]	giv[73]	_	_
9-19	1463-1466	the	abstract[73]|abstract[74]	giv[73]|giv[74]	coref	10-3[0_74]
9-20	1467-1472	virus	abstract[73]|abstract[74]	giv[73]|giv[74]	_	_
9-21	1473-1474	.	_	_	_	_

#Text=Therefore , IAV infection is linked closely to metabolism , and the proliferation of the virus also is inseparable from the host metabolism .
10-1	1475-1484	Therefore	_	_	_	_
10-2	1485-1486	,	_	_	_	_
10-3	1487-1490	IAV	object|abstract[76]	giv|giv[76]	coref|coref|coref|coref	10-15[79_0]|13-8[111_76]|10-15[79_0]|13-8[111_76]
10-4	1491-1500	infection	abstract[76]	giv[76]	_	_
10-5	1501-1503	is	_	_	_	_
10-6	1504-1510	linked	_	_	_	_
10-7	1511-1518	closely	_	_	_	_
10-8	1519-1521	to	_	_	_	_
10-9	1522-1532	metabolism	abstract	giv	coref	10-21[81_0]
10-10	1533-1534	,	_	_	_	_
10-11	1535-1538	and	_	_	_	_
10-12	1539-1542	the	abstract[78]	giv[78]	_	_
10-13	1543-1556	proliferation	abstract[78]	giv[78]	_	_
10-14	1557-1559	of	abstract[78]	giv[78]	_	_
10-15	1560-1563	the	abstract[78]|abstract[79]	giv[78]|giv[79]	coref	12-10[0_79]
10-16	1564-1569	virus	abstract[78]|abstract[79]	giv[78]|giv[79]	_	_
10-17	1570-1574	also	_	_	_	_
10-18	1575-1577	is	_	_	_	_
10-19	1578-1589	inseparable	_	_	_	_
10-20	1590-1594	from	_	_	_	_
10-21	1595-1598	the	abstract[81]	giv[81]	coref	15-9[127_81]
10-22	1599-1603	host	person|abstract[81]	new|giv[81]	coref	11-14
10-23	1604-1614	metabolism	abstract[81]	giv[81]	_	_
10-24	1615-1616	.	_	_	_	_

#Text=This changing trend in small molecule metabolites may serve as a characterization of host – pathogen interactions to monitor immune status .
11-1	1617-1621	This	abstract[82]	new[82]	_	_
11-2	1622-1630	changing	abstract[82]	new[82]	_	_
11-3	1631-1636	trend	abstract[82]	new[82]	_	_
11-4	1637-1639	in	abstract[82]	new[82]	_	_
11-5	1640-1645	small	abstract[82]|substance[84]	new[82]|giv[84]	_	_
11-6	1646-1654	molecule	abstract[82]|abstract|substance[84]	new[82]|new|giv[84]	_	_
11-7	1655-1666	metabolites	abstract[82]|substance[84]	new[82]|giv[84]	_	_
11-8	1667-1670	may	_	_	_	_
11-9	1671-1676	serve	_	_	_	_
11-10	1677-1679	as	_	_	_	_
11-11	1680-1681	a	_	_	_	_
11-12	1682-1698	characterization	_	_	_	_
11-13	1699-1701	of	_	_	_	_
11-14	1702-1706	host	person	giv	coref	17-23[147_0]
11-15	1707-1708	–	_	_	_	_
11-16	1709-1717	pathogen	abstract|abstract[87]	new|new[87]	_	_
11-17	1718-1730	interactions	abstract[87]	new[87]	_	_
11-18	1731-1733	to	_	_	_	_
11-19	1734-1741	monitor	_	_	_	_
11-20	1742-1748	immune	abstract[88]	new[88]	_	_
11-21	1749-1755	status	abstract[88]	new[88]	_	_
11-22	1756-1757	.	_	_	_	_

#Text=Although significant progress has been made toward an anti-influenza virus drug discovery , including M2 ion channel blockers , neuraminidase inhibitors , and polymerase inhibitors , challenges posed by drug toxicity and viruses with genetic resistance remain a serious problem .
12-1	1758-1766	Although	_	_	_	_
12-2	1767-1778	significant	abstract[89]	new[89]	_	_
12-3	1779-1787	progress	abstract[89]	new[89]	_	_
12-4	1788-1791	has	_	_	_	_
12-5	1792-1796	been	_	_	_	_
12-6	1797-1801	made	_	_	_	_
12-7	1802-1808	toward	_	_	_	_
12-8	1809-1811	an	abstract[92]	new[92]	_	_
12-9	1812-1826	anti-influenza	abstract[92]	new[92]	_	_
12-10	1827-1832	virus	abstract|abstract[92]	giv|new[92]	coref	13-8
12-11	1833-1837	drug	substance|abstract[92]	new|new[92]	coref	12-30
12-12	1838-1847	discovery	abstract[92]	new[92]	_	_
12-13	1848-1849	,	abstract[92]	new[92]	_	_
12-14	1850-1859	including	abstract[92]	new[92]	_	_
12-15	1860-1862	M2	abstract[92]|abstract|abstract[95]	new[92]|new|new[95]	_	_
12-16	1863-1866	ion	abstract[92]|abstract[95]	new[92]|new[95]	_	_
12-17	1867-1874	channel	abstract[92]|place|abstract[95]	new[92]|new|new[95]	_	_
12-18	1875-1883	blockers	abstract[92]|abstract[95]	new[92]|new[95]	_	_
12-19	1884-1885	,	abstract[92]	new[92]	_	_
12-20	1886-1899	neuraminidase	abstract[92]|abstract|object[97]	new[92]|new|new[97]	_	_
12-21	1900-1910	inhibitors	abstract[92]|object[97]	new[92]|new[97]	_	_
12-22	1911-1912	,	abstract[92]	new[92]	_	_
12-23	1913-1916	and	abstract[92]	new[92]	_	_
12-24	1917-1927	polymerase	abstract[92]|object|object[99]	new[92]|new|new[99]	_	_
12-25	1928-1938	inhibitors	abstract[92]|object[99]	new[92]|new[99]	_	_
12-26	1939-1940	,	_	_	_	_
12-27	1941-1951	challenges	abstract	new	_	_
12-28	1952-1957	posed	_	_	_	_
12-29	1958-1960	by	_	_	_	_
12-30	1961-1965	drug	substance|abstract[102]	giv|new[102]	_	_
12-31	1966-1974	toxicity	abstract[102]	new[102]	_	_
12-32	1975-1978	and	_	_	_	_
12-33	1979-1986	viruses	object[103]	giv[103]	_	_
12-34	1987-1991	with	object[103]	giv[103]	_	_
12-35	1992-1999	genetic	object[103]|abstract[104]	giv[103]|new[104]	_	_
12-36	2000-2010	resistance	object[103]|abstract[104]	giv[103]|new[104]	_	_
12-37	2011-2017	remain	_	_	_	_
12-38	2018-2019	a	abstract[105]	new[105]	_	_
12-39	2020-2027	serious	abstract[105]	new[105]	_	_
12-40	2028-2035	problem	abstract[105]	new[105]	_	_
12-41	2036-2037	.	_	_	_	_

#Text=Previous research demonstrated the metabolic effects of influenza virus infection in Madin – Darby canine kidney ( MDCK ) cells , displaying the intra- and extra-cellular metabolite profiling upon IAV infection .
13-1	2038-2046	Previous	abstract[106]	new[106]	_	_
13-2	2047-2055	research	abstract[106]	new[106]	_	_
13-3	2056-2068	demonstrated	_	_	_	_
13-4	2069-2072	the	abstract[108]	new[108]	_	_
13-5	2073-2082	metabolic	abstract|abstract[108]	new|new[108]	coref	14-10
13-6	2083-2090	effects	abstract[108]	new[108]	_	_
13-7	2091-2093	of	abstract[108]	new[108]	_	_
13-8	2094-2103	influenza	abstract[108]|abstract|abstract[111]	new[108]|giv|giv[111]	coref|coref|coref|coref	13-9|13-30[117_111]|13-9|13-30[117_111]
13-9	2104-2109	virus	abstract[108]|abstract|abstract[111]	new[108]|giv|giv[111]	coref	13-30
13-10	2110-2119	infection	abstract[108]|abstract[111]	new[108]|giv[111]	_	_
13-11	2120-2122	in	abstract[108]|abstract[111]	new[108]|giv[111]	_	_
13-12	2123-2128	Madin	abstract[108]|abstract[111]|person	new[108]|giv[111]|new	_	_
13-13	2129-2130	–	abstract[108]|abstract[111]	new[108]|giv[111]	_	_
13-14	2131-2136	Darby	abstract[108]|abstract[111]	new[108]|giv[111]	_	_
13-15	2137-2143	canine	abstract[108]|abstract[111]	new[108]|giv[111]	_	_
13-16	2144-2150	kidney	abstract[108]|abstract[111]	new[108]|giv[111]	_	_
13-17	2151-2152	(	abstract[108]|abstract[111]	new[108]|giv[111]	_	_
13-18	2153-2157	MDCK	abstract[108]|abstract[111]|object	new[108]|giv[111]|new	_	_
13-19	2158-2159	)	abstract[108]|abstract[111]	new[108]|giv[111]	_	_
13-20	2160-2165	cells	abstract[108]|abstract[111]|object	new[108]|giv[111]|giv	coref	15-15[131_0]
13-21	2166-2167	,	_	_	_	_
13-22	2168-2178	displaying	_	_	_	_
13-23	2179-2182	the	substance[115]	new[115]	coref	16-2[0_115]
13-24	2183-2189	intra-	substance[115]	new[115]	_	_
13-25	2190-2193	and	substance[115]	new[115]	_	_
13-26	2194-2208	extra-cellular	substance[115]	new[115]	_	_
13-27	2209-2219	metabolite	substance[115]	new[115]	_	_
13-28	2220-2229	profiling	_	_	_	_
13-29	2230-2234	upon	_	_	_	_
13-30	2235-2238	IAV	substance|abstract[117]	giv|giv[117]	coref|coref|coref|coref	14-17|14-17[122_117]|14-17|14-17[122_117]
13-31	2239-2248	infection	abstract[117]	giv[117]	_	_
13-32	2249-2250	.	_	_	_	_

#Text=Little is known , however , about the systemic metabolic dynamics during the early stage of virus infection .
14-1	2251-2257	Little	_	_	_	_
14-2	2258-2260	is	_	_	_	_
14-3	2261-2266	known	_	_	_	_
14-4	2267-2268	,	_	_	_	_
14-5	2269-2276	however	_	_	_	_
14-6	2277-2278	,	_	_	_	_
14-7	2279-2284	about	_	_	_	_
14-8	2285-2288	the	abstract[119]	new[119]	_	_
14-9	2289-2297	systemic	abstract[119]	new[119]	_	_
14-10	2298-2307	metabolic	abstract|abstract[119]	giv|new[119]	_	_
14-11	2308-2316	dynamics	abstract[119]	new[119]	_	_
14-12	2317-2323	during	abstract[119]	new[119]	_	_
14-13	2324-2327	the	abstract[119]|abstract[120]	new[119]|new[120]	_	_
14-14	2328-2333	early	abstract[119]|abstract[120]	new[119]|new[120]	_	_
14-15	2334-2339	stage	abstract[119]|abstract[120]	new[119]|new[120]	_	_
14-16	2340-2342	of	abstract[119]|abstract[120]	new[119]|new[120]	_	_
14-17	2343-2348	virus	abstract[119]|abstract[120]|abstract|abstract[122]	new[119]|new[120]|giv|giv[122]	coref|coref|coref|coref	15-11|15-11[130_122]|15-11|15-11[130_122]
14-18	2349-2358	infection	abstract[119]|abstract[120]|abstract[122]	new[119]|new[120]|giv[122]	_	_
14-19	2359-2360	.	_	_	_	_

#Text=During our study , we analyze changes in metabolism upon influenza virus infection in human cells during the first infectious cycle via metabolomics .
15-1	2361-2367	During	_	_	_	_
15-2	2368-2371	our	person|abstract[124]	acc|new[124]	ana|ana	15-5|15-5
15-3	2372-2377	study	abstract[124]	new[124]	_	_
15-4	2378-2379	,	_	_	_	_
15-5	2380-2382	we	person	giv	ana	17-1
15-6	2383-2390	analyze	_	_	_	_
15-7	2391-2398	changes	abstract	new	_	_
15-8	2399-2401	in	_	_	_	_
15-9	2402-2412	metabolism	abstract[127]	giv[127]	coref	16-12[139_127]
15-10	2413-2417	upon	abstract[127]	giv[127]	_	_
15-11	2418-2427	influenza	abstract[127]|abstract|abstract[130]	giv[127]|giv|giv[130]	coref|coref|coref|coref	15-12|17-17[145_130]|15-12|17-17[145_130]
15-12	2428-2433	virus	abstract[127]|abstract|abstract[130]	giv[127]|giv|giv[130]	coref	17-43
15-13	2434-2443	infection	abstract[127]|abstract[130]	giv[127]|giv[130]	_	_
15-14	2444-2446	in	_	_	_	_
15-15	2447-2452	human	object[131]	giv[131]	_	_
15-16	2453-2458	cells	object[131]	giv[131]	_	_
15-17	2459-2465	during	_	_	_	_
15-18	2466-2469	the	abstract[132]	new[132]	_	_
15-19	2470-2475	first	abstract[132]	new[132]	_	_
15-20	2476-2486	infectious	abstract[132]	new[132]	_	_
15-21	2487-2492	cycle	abstract[132]	new[132]	_	_
15-22	2493-2496	via	abstract[132]	new[132]	_	_
15-23	2497-2509	metabolomics	abstract[132]|abstract	new[132]|new	_	_
15-24	2510-2511	.	_	_	_	_

#Text=Early metabolite analysis will throw new light on the activation of the innate immune metabolism .
16-1	2512-2517	Early	abstract[135]	new[135]	_	_
16-2	2518-2528	metabolite	substance|abstract[135]	giv|new[135]	_	_
16-3	2529-2537	analysis	abstract[135]	new[135]	_	_
16-4	2538-2542	will	_	_	_	_
16-5	2543-2548	throw	_	_	_	_
16-6	2549-2552	new	abstract[136]	new[136]	_	_
16-7	2553-2558	light	abstract[136]	new[136]	_	_
16-8	2559-2561	on	_	_	_	_
16-9	2562-2565	the	event[137]	new[137]	_	_
16-10	2566-2576	activation	event[137]	new[137]	_	_
16-11	2577-2579	of	event[137]	new[137]	_	_
16-12	2580-2583	the	event[137]|abstract[139]	new[137]|giv[139]	_	_
16-13	2584-2590	innate	event[137]|abstract[139]	new[137]|giv[139]	_	_
16-14	2591-2597	immune	event[137]|object|abstract[139]	new[137]|giv|giv[139]	_	_
16-15	2598-2608	metabolism	event[137]|abstract[139]	new[137]|giv[139]	_	_
16-16	2609-2610	.	_	_	_	_

#Text=We believe that the results of this work will elucidate the activation of innate immunity to viral infection from the perspective of the host and provide new control strategies for the development of novel drugs and the treatment and prevention of influenza virus infection .
17-1	2611-2613	We	person	giv	_	_
17-2	2614-2621	believe	_	_	_	_
17-3	2622-2626	that	_	_	_	_
17-4	2627-2630	the	abstract[141]	new[141]	_	_
17-5	2631-2638	results	abstract[141]	new[141]	_	_
17-6	2639-2641	of	abstract[141]	new[141]	_	_
17-7	2642-2646	this	abstract[141]|abstract[142]	new[141]|new[142]	_	_
17-8	2647-2651	work	abstract[141]|abstract[142]	new[141]|new[142]	_	_
17-9	2652-2656	will	_	_	_	_
17-10	2657-2666	elucidate	_	_	_	_
17-11	2667-2670	the	abstract[143]	new[143]	_	_
17-12	2671-2681	activation	abstract[143]	new[143]	_	_
17-13	2682-2684	of	abstract[143]	new[143]	_	_
17-14	2685-2691	innate	abstract[143]|abstract[144]	new[143]|giv[144]	_	_
17-15	2692-2700	immunity	abstract[143]|abstract[144]	new[143]|giv[144]	_	_
17-16	2701-2703	to	abstract[143]|abstract[144]	new[143]|giv[144]	_	_
17-17	2704-2709	viral	abstract[143]|abstract[144]|abstract[145]	new[143]|giv[144]|giv[145]	coref	17-42[155_145]
17-18	2710-2719	infection	abstract[143]|abstract[144]|abstract[145]	new[143]|giv[144]|giv[145]	_	_
17-19	2720-2724	from	abstract[143]|abstract[144]	new[143]|giv[144]	_	_
17-20	2725-2728	the	abstract[143]|abstract[144]|abstract[146]	new[143]|giv[144]|new[146]	_	_
17-21	2729-2740	perspective	abstract[143]|abstract[144]|abstract[146]	new[143]|giv[144]|new[146]	_	_
17-22	2741-2743	of	abstract[143]|abstract[144]|abstract[146]	new[143]|giv[144]|new[146]	_	_
17-23	2744-2747	the	abstract[143]|abstract[144]|abstract[146]|person[147]	new[143]|giv[144]|new[146]|giv[147]	_	_
17-24	2748-2752	host	abstract[143]|abstract[144]|abstract[146]|person[147]	new[143]|giv[144]|new[146]|giv[147]	_	_
17-25	2753-2756	and	_	_	_	_
17-26	2757-2764	provide	_	_	_	_
17-27	2765-2768	new	abstract[149]	giv[149]	_	_
17-28	2769-2776	control	person|abstract[149]	new|giv[149]	_	_
17-29	2777-2787	strategies	abstract[149]	giv[149]	_	_
17-30	2788-2791	for	abstract[149]	giv[149]	_	_
17-31	2792-2795	the	abstract[149]|abstract[150]	giv[149]|new[150]	_	_
17-32	2796-2807	development	abstract[149]|abstract[150]	giv[149]|new[150]	_	_
17-33	2808-2810	of	abstract[149]|abstract[150]	giv[149]|new[150]	_	_
17-34	2811-2816	novel	abstract[149]|abstract[150]|substance[151]	giv[149]|new[150]|new[151]	_	_
17-35	2817-2822	drugs	abstract[149]|abstract[150]|substance[151]	giv[149]|new[150]|new[151]	_	_
17-36	2823-2826	and	abstract[149]|abstract[150]	giv[149]|new[150]	_	_
17-37	2827-2830	the	abstract[149]|abstract[150]|abstract[152]	giv[149]|new[150]|new[152]	_	_
17-38	2831-2840	treatment	abstract[149]|abstract[150]|abstract[152]	giv[149]|new[150]|new[152]	_	_
17-39	2841-2844	and	abstract[149]|abstract[150]	giv[149]|new[150]	_	_
17-40	2845-2855	prevention	abstract[149]|abstract[150]|abstract[153]	giv[149]|new[150]|new[153]	_	_
17-41	2856-2858	of	abstract[149]|abstract[150]|abstract[153]	giv[149]|new[150]|new[153]	_	_
17-42	2859-2868	influenza	abstract[149]|abstract[150]|abstract[153]|abstract[155]	giv[149]|new[150]|new[153]|giv[155]	_	_
17-43	2869-2874	virus	abstract[149]|abstract[150]|abstract[153]|abstract|abstract[155]	giv[149]|new[150]|new[153]|giv|giv[155]	_	_
17-44	2875-2884	infection	abstract[149]|abstract[150]|abstract[153]|abstract[155]	giv[149]|new[150]|new[153]|giv[155]	_	_
17-45	2885-2886	.	_	_	_	_
